SGP (SpyGlass Pharma) Accounts Receivable: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SGP SpyGlass Pharma Inc SGP
12 GF Score
Price $25.07
View Full Analysis

What is SpyGlass Pharma Accounts Receivable?

SpyGlass Pharma SGP -0.59% 12 Accounts Receivable is $0.00 Mil as of Jun. 2026. GuruFocus rates SGP with a GF Score™ of 12/100.

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. SpyGlass Pharma's accounts receivables for the quarter that ended in Jun. 2026 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. SpyGlass Pharma's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was $6.67.


SpyGlass Pharma Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

SpyGlass Pharma's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), SpyGlass Pharma's accounts receivable are only considered to be worth 75% of book value:

SpyGlass Pharma's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(234.186+0.75 * 0+0.5 * 0-11.069
-0-0)/33.440
=6.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


SpyGlass Pharma Accounts Receivable Related Terms


SpyGlass Pharma Accounts Receivable Historical Data

* Premium members only.

The historical data trend for SpyGlass Pharma's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SpyGlass Pharma Accounts Receivable Chart

SpyGlass Pharma Annual Data
Trend Dec23 Dec24 Dec25
Accounts Receivable
0.00 0.00 0.00

SpyGlass Pharma Quarterly Data
Dec23 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Receivable Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
SGP
12GF Score
SpyGlass Pharma Inc SGP
Accounts Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SpyGlass Pharma Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Frequently Asked Questions Learn more about Accounts Receivable →
What does a Accounts Receivable of $0.00 Mil mean?
SpyGlass Pharma (SGP) has a Accounts Receivable of $0.00 Mil as of Jun. 2026. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on SpyGlass Pharma and its competitors.
Is SpyGlass Pharma's Accounts Receivable too high?
SpyGlass Pharma's current Accounts Receivable is $0.00 Mil. Overall, SpyGlass Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SpyGlass Pharma's Accounts Receivable compare to RIGL and NGNE?
SpyGlass Pharma's Accounts Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Biotechnology company?
A good Accounts Receivable depends on the Biotechnology industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on SpyGlass Pharma and its competitors. SpyGlass Pharma's current Accounts Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SpyGlass Pharma stock overvalued right now?
SpyGlass Pharma (SGP) has a current Accounts Receivable of $0.00 Mil. The current Accounts Receivable is $0.00 Mil. SpyGlass Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For SpyGlass Pharma (SGP), the current Accounts Receivable is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SpyGlass Pharma Business Description

Address 27061 Aliso Creek Road, Suite 100, Aliso Viejo, CA, USA, 92656
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
12GF Score

Get the complete analysis for SGP

Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.07
Price